Cerenis names Richard Pasternak chair
This article was originally published in Scrip
Executive Summary
Cerenis Therapeutics, a biopharmaceutical company developing an engineered human apoA-I-containing pre-β HDL mimetic for the treatment of cardiovascular disease, has appointed Dr Richard C Pasternak chair of the board of directors. He succeeds Dr Jean-Pierre Garnier, who is stepping down from the company for personal reasons. Dr Pasternak has spent the last 35 years as an academic and biopharmaceutical clinician-scientist, with a long-standing research interest in vascular disease, lipid disorders and atherosclerosis, as well as prevention and patterns of practice and disease management. He has been a non-executive director on Cerenis' board since November 2011.